Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030


Real-time Estimate Quote. Real-time Estimate Cboe BZX - 09/24 12:44:29 pm
68.64 USD   -2.36%
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
09/15China's biotech sector comes of age with big licensing deals, global ambitions
09/13I-MAB : Added to FTSE ESG Index Series
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I Mab : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease

07/30/2021 | 10:29am EDT
Planningunderwayfor a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease

SHANGHAI, China and GAITHERSBURG, MD., July 30, 2021- I-Mab (the 'Company') (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, developmentand commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drugto treat Alzheimer's disease, enabling a Phase 1 clinical trialto be initiated. Worldwide, around 50 million people are living with Alzheimer's disease or other dementias, with no cure available.

'Advancing Protollininto clinic is a critical milestone in the search to develop novel therapies for this devastating disease, and we are honoredto be engaging in a planning process with partners around the globe and contributingour expertise,' said Dr.Jingwu Zang, Founder, Chairman and Director of I-Mab.

Protollinis a new type of immunotherapy aimed at stimulating the innate immune system to activate a response against the build-upof beta amyloid protein plaques and subsequent tau tangles that cause memory loss.

Brigham and Women's Hospitaland Inspirevax(formerly Biodextris) granted I-Mab and Nhwaglobal exclusive licenses to develop, manufacture, and commercialize Protollin, and Biodextriswill manufacture and supply Protollinfor preclinical and clinical studies until the recruitment of the first patient in the Phase 1b MAD study. I-Mab will develop and commercialize Protollinoutside of the Greater China territory, while Nhwawill develop and commercialize the drug in mainland China, Hong Kong, Macau, and Taiwan.


About Protollin

Protollinis a novel immunotherapy aimed at stimulating the innate immune system. It is composed of outer membrane proteins of bacteria complexed with lipopolysaccharides (LPS). There are preclinical data indicating that it can modulate immune cells and has the potential to treat disorders with an immune component. Delivery of Protollinthrough nasal spray will enable the molecule reach brain and stimulate the expected immune response. The initial data support its potential application in neurodegenerative diseases such as Alzheimer's disease.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon,commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facilities and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.comand follow I-Mab on LinkedIn, Twitterand WeChat.

Special Note Regarding Forward-Looking Statements

This press release includes certain disclosures which contain 'forward-looking statements.' You can identify forward-looking statements because they contain words such as 'anticipate' and 'expected.' Forward-looking statements are based on I-Mab, Jiangsu Nhwa, and Inspirevax's(formerly Biodextris)current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab, Jiangsu Nhwa, and Inspirevax(formerly Biodextris)undertake no obligation to publicly update or revise any forward-looking statements, whether as a result ofnew information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Jielun Zhu
Chief Financial Officer


+86 21 6057 8000

Gigi Feng
Chief Communications Officer


+86 21 6057 8000

Investor Inquiries

The PiacenteGroup, Inc.

Emilie Wu

E-mail: emilie@thepiacentegroup.com

Office line: +86 21 6039 8363


I-Mab published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 14:28:04 UTC.

ę Publicnow 2021
All news about I-MAB
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
09/15China's biotech sector comes of age with big licensing deals, global ambitions
09/13I-MAB : Added to FTSE ESG Index Series
09/02I-MAB : Added to FTSE Russell Global Equity Index Series
09/01I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating
08/31I MAB : H1 Loss Widens
08/31I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Six ..
08/31I-Mab Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
08/30I-MAB : Announces Upcoming Participation at September Conferences
08/27I MAB : Announces Upcoming Participation at September Conferences
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 78,2 M - -
Net income 2021 -209 M - -
Net cash 2021 611 M - -
P/E ratio 2021 -34,5x
Yield 2021 -
Capitalization 5 410 M 5 410 M -
EV / Sales 2021 61,4x
EV / Sales 2022 24,7x
Nbr of Employees 228
Free-Float 98,7%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 15
Last Close Price 70,30 $
Average target price 94,73 $
Spread / Average Target 34,7%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
Jielun Zhu Chief Financial Officer & Director
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB49.10%5 410
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750